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Summary
TRF1 is a key component of the telomere-capping complex and binds double-strand telomeric DNA as homodimers. So far, it is not
clear whether TRF1 dimerization coincides with its telomere binding or is actively controlled before it binds the telomere, and in the
latter case, how this event might affect its telomere association. We previously found that TRF1 dimerization and its telomere binding
can be increased by GNL3L, which is the vertebrate paralogue of nucleostemin (NS). Here, we show that NS and GNL3L bind TRF1
directly but competitively through two separate domains of TRF1. In contrast to GNL3L, NS prevents TRF1 dimerization through a
mechanism not determined by its ability to displace TRF1-bound GNL3L. Furthermore, NS is capable of shortening the dynamic
association of TRF1 with the telomere in normal and TRF2DBDM-induced telomere-damaged cells without affecting the amount of
telomere-bound TRF1 proteins in vivo. Importantly, NS displays a protective function against the formation of telomere-dysfunction-
induced foci. This work demonstrates that TRF1 dimerization is actively and oppositely regulated by NS and GNL3L
extrachromosomally. Changing the relative amount of TRF1 monomers versus dimers in the nucleoplasm might affect the dynamic
association of TRF1 with the telomere and the repair of damaged telomeres.
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Introduction
Telomeric repeat-binding factor 1 (TRF1) is a component of the
telomere-capping complex, also known as shelterin or telosome,
which consists of six core proteins: TRF1, TRF2, TIN2 (TRF1-
interacting nuclear protein 2), POT1 (protection of telomeres
protein 1), TPP1 (also known as adrenocortical dysplasia
homolog, ACD) and RAP1 (de Lange, 2005; Songyang and
Liu, 2006). The telomere-capping complex organizes
chromosomal ends into a high-order structure and has a crucial
role in maintaining their stability. TRF1 serves the important
functions of protecting telomeres (Martinez et al., 2009),
preventing telomere elongation (van Steensel and de Lange,
1997), controlling the mitotic transit (Zhou et al., 2003) and
regulating ALT (alternative lengthening of telomere)-associated
PML body (APB) formation in telomerase-inactive cells (Jiang
et al., 2007; Potts and Yu, 2005). TRF1 protein is post-
translationally modified by phosphorylation, ADP ribosylation,
ubiquitylation, and homodimerization (Chang et al., 2003; Chong
et al., 1995; Kim et al., 2008; Lee et al., 2006; Smith et al., 1998;
Wu et al., 2008). Dimerization allows TRF1 to form proper
configuration and bind double-strand telomeric DNA repeats
through its Myb domain (Bianchi et al., 1997; Broccoli et al.,
1997). Even though TRF1 dimerization was observed both in a
complex with DNA and by a yeast two-hybrid assay (Bianchi
et al., 1997), it is not clear whether this event is actively regulated
while TRF1 is in the nucleoplasm or occurs concomitantly with
the formation of the telomere-capping complex.
We first discovered that nucleostemin (NS) is a TRF1-binding
protein that accelerates the degradation of TRF1 (Zhu et al.,
2006). NS belongs to a novel family of nucleolar GTP-binding
proteins (Tsai and Meng, 2009), and is found preferentially
expressed by multiple stem cell types, human cancers and adult
regenerating tissues (Baddoo et al., 2003; Maki et al., 2007;
Ohmura et al., 2008; Siddiqi et al., 2008; Tsai and McKay, 2002).
It is required for early embryogenesis and the maintenance of
continuous cell proliferation (Tsai and Meng, 2009; Zhu et al.,
2006). In later studies, we found that its vertebrate paralogue,
GNL3L (guanine nucleotide binding protein-like 3-like), can also
bind TRF1 and promote its homodimerization and telomere
association without being physically bound to the telomere (Zhu
et al., 2009). In contrast to the NS effect on TRF1, GNL3L shows
the ability to promote TRF1 stability by preventing its
ubiquitylation and degradation. Those previous findings
indicate that the TRF1 protein complex might be modulated
actively and dynamically before it binds the telomere (Tsai,
2009).
To further our understanding of this new ‘pre-telomeric’
regulation of TRF1, we set out to investigate how NS controls the
biochemical interaction and telomeric association of TRF1. Our
results showed that NS and GNL3L both bind TRF1 directly but
competitively. Whereas GNL3L promotes the dimerization and
telomeric association of TRF1 (Zhu et al., 2009), NS diminishes
TRF1 dimerization independently of its ability to dissociate
GNL3L from TRF1. Functional studies demonstrated that NS is
capable of shortening the dynamic association of TRF1 with the
telomere in normal and TRF2DBDM-induced telomere-damaged
cells without affecting the amount of telomere-bound TRF1



















N-terminal basic domain and C-terminal Myb domain.
TRF2DBDM lacks telomere-binding activity, thus acting as a
dominant-negative allele of TRF2, and has been used to
destabilize the telomere-capping complex and trigger telomere
damage (van Steensel et al., 1998). Importantly, we found that
NS has a protective role against TRF2DBDM-induced telomere
damage. This work reveals a novel TRF1 regulatory mechanism
that operates bidirectionally and extrachromosomally.
Results
NS and GNL3L bind directly to separate domains of TRF1
We have previously shown that TRF1 coexists in the same
protein complex with NS or with GNL3L (Zhu et al., 2009; Zhu
et al., 2006). To demonstrate that NS or GNL3L directly binds
TRF1, we isolated bacterially expressed NS and GNL3L proteins
and examined their binding with purified GST–TRF1 proteins by
affinity pull-down assays. Immunoblotting of the input, unbound
supernatant (Sup) and retained fractions (Ret) confirmed that
both NS and GNL3L can specifically and directly bind TRF1
(Fig. 1A). The amounts of NS in the unbound (Sup) and bound
(Ret) fractions relative to the input are less than that of GNL3L,
which might be caused by the rapid degradation of purified NS
proteins. The TRF1-interactive domain of NS was mapped by
deletions made on the basic (B), coiled-coil (C), GTP-binding
(G), intermediate (I) or A-domain of NS (Fig. 1B). Unlike the
TRF1-interacting G-domain of GNL3L (Zhu et al., 2009),
binding between TRF1 and NS requires the I-domain of NS.
Conversely, the NS-interactive domain of TRF1 was determined
by testing the NS binding of TRF1 mutants deleted of the A-
domain, HBD (homodimerization domain), UD (undefined) or
Myb domain (Fig. 1C). Whereas GNL3L interacts with the HBD
domain of TRF1 (Zhu et al., 2009), binding between TRF1 and
NS requires the UD domain of TRF1. The lack of binding
capability of NSDI or TRF1DUD should not be caused by protein
misfolding because these proteins are capable of binding MDM2
and GNL3L, respectively (Meng et al., 2008; Zhu et al., 2009).
To exclude another possibility that the differential NS-binding
activities of TRF1 mutants might result from their distinct
subcellular localization, confocal studies were conducted in HeLa
cells and showed that both the NS binding (TRF1DMyb) and
non-binding (TRF1DUD) mutants are located outside the
nucleolus (Fig. 1D). Similar findings were observed in U2OS
cells (data not shown). These results demonstrate that NS and
GNL3L bind directly to separate domains of TRF1.
Fig. 1. NS and GNL3L bind directly to two separate domains of TRF1. (A) Purified NS and GNL3L proteins (40 mg) were incubated with purified Sepharose-
bound GST–TRF1 protein (4 mg). Fractions of the input (1/100th), unbound supernatant (Sup, 1/100th), and retained lysates (Ret, 1/10th–1/20th) were
immunoblotted (IB) with anti-NS and anti-GNL3L (G3L) antibodies. The pull-down results confirmed that NS and GNL3L bind TRF1 directly. (B) GST pull-
down assays showing that the I-domain of NS is required for its TRF1 interaction. (C) Conversely, the UD domain of TRF1 is required for its interaction with NS.
Bottom panels in B and C depict the deletion mutants of NS and TRF1. Bent lines and numbers denote the deleted regions and amino acid positions, respectively.
B, basic; C, coiled-coil; G, GTP-binding; I, intermediate; A, acidic; HBD, homodimerization; UD, undefined domain. (D) Confocal images of GFP-fused wild-
type and mutant TRF1 proteins in HeLa cells. Nucleoli are labeled by anti-B23 staining. Scale bar: 20 mm.


















NS negatively regulates the GNL3L binding and
homodimerization of TRF1
To interrogate the TRF1-binding relationship between NS and
GNL3L, we asked whether NS and GNL3L form hetero-trimeric
complexes with TRF1 or bind TRF1 as separate hetero-dimeric
complexes. To address this issue, we first examined the
coimmunoprecipitation of endogenous NS, TRF1 and GNL3L,
and found only TRF1 in the NS protein complex (Fig. 2A). Next,
we tested whether these three proteins can form hetero-trimeric
complexes. NS (Myc), GNL3L (HA) and TRF1 (FLAG) were
coexpressed in HEK293 cells, and the TRF1 and GNL3L co-
complex was purified by sequential anti-FLAG and anti-HA
immunoprecipitation. Anti-Myc western blots showed that the
hetero-trimeric complex does exist, but accounts for only a small
fraction of the hetero-dimeric complex of GNL3L and TRF1 even
upon overexpression (Fig. 2B). These results indicate that the
majority of NS and GNL3L bind TRF1 separately, but a small
portion might form a heterotrimeric complex with TRF1. To
examine the possibility that NS and GNL3L compete against each
other for TRF1 binding, GST-fused TRF1 proteins were purified to
pull down lysates containing a fixed amount of Myc-tagged
GNL3L and increasing amounts of HA-tagged NS (Fig. 2C, left).
The total protein concentrations were adjusted to the same levels in
all samples. The results showed that NS is capable of blocking
GNL3L binding to TRF1 in a dose-dependent manner.
Reciprocally, GNL3L can also compete against NS for TRF1
binding (Fig. 2C, right). One major TRF1-binding protein in the
telomere-capping complex is TIN2. GST-binding competition
experiments showed that NS and TIN2 do not interfere with each
other’s binding to TRF1 (Fig. 2D). TRF1 is also known to form
homodimers. To investigate the NS role in regulating TRF1
dimerization, GST–TRF1 was used to pull down lysates with the
same amount of Myc-tagged TRF1 and increasing amounts of NS.
In contrast to the effect of GNL3L on TRF1 dimerization (Zhu
et al., 2009), addition of NS reduced the association between the
Myc-tagged TRF1 and GST–TRF1 in a dose-dependent manner
(Fig. 2E). Together, these results demonstrate that NS prevents
TRF1 from binding to GNL3L and to itself, but does not interfere
with the interaction of TRF1 with its partner at the telomere, TIN2.
NS structures required for its inhibition of GNL3L binding
and dimerization of TRF1
NS inhibition of TRF1 homodimerization might be mediated by
its role in competing against GNL3L for TRF1 binding, because
GNL3L is known to promote TRF1 homodimerization (Zhu et al.,
2009). If true, its abilities to block TRF1 dimerization and
GNL3L binding should correlate. To test this idea, we examined
the NS protein structures required to inhibit the GNL3L binding
or dimerization of TRF1. Our results showed that the ability of
NS to displace TRF1-bound GNL3L was mostly abolished by
deleting its TRF1-interactive I-domain (Fig. 3A), but not affected
by the deletion of the B-, G- or A-domain of NS, or by the
G256V mutation that abolishes its GTP-binding capability
(Fig. 3B–E). Reciprocally, the ability of GNL3L to displace
TRF1-bound NS only required its TRF1-interactive G-domain
(Fig. 3G), and was not decreased by the deletion of its BC- or I-
domain (Fig. 3H,I) or the G253V mutation that corresponds to
the G256V mutation of NS (Fig. 3J).
Fig. 2. NS inhibits GNL3L binding and homodimerization of TRF1. (A) Immunoprecipitation (IP) of endogenous NS complex copurified TRF1 but not
GNL3L. (B) Two-step coimmunoprecipitation (coIP) was used to determine whether NS (Myc-tagged), GNL3L (HA-tagged) and TRF1 (FLAG-tagged) are
capable of forming hetero-trimeric complexes. The TRF1 complex was precipitated using anti-FLAG antibody and eluted using FLAG peptide. Then the TRF1–
GNL3L co-complex was purified by anti-HA immunoprecipitation. The amount of the hetero-trimeric complex (detected by immunoblotting the TRF1–GNL3L
co-complex with anti-Myc antibody) represents a small fraction of the TRF1–GNL3L co-complex even upon overexpression. (C) Agarose-bound GST–TRF1 was
incubated with lysates containing a fixed amount of GNL3L (Myc) and increasing amounts of NS (HA) or vice versa. Increasing the amount of NS significantly
reduces the signal of TRF1-bound GNL3L (left). Reciprocally, increasing the amount of GNL3L also decreases NS binding to GST–TRF1 (right). (D) GST pull-
down competition experiments show that NS (HA) does not affect the binding between TIN2 (Myc) and GST–TRF1 (left); nor does TIN2 (Myc) change the
binding between NS (HA) and GST–TRF1 (right). (E) Increasing the amount of NS significantly decreases the binding efficiency between TRF1 (Myc) and GST–
TRF1 in a dose-dependent manner.


















With respect to the NS effect on blocking TRF1
homodimerization, our data showed that this NS activity was
completely abolished by deleting its I-domain (NSDI, Fig. 4A),
B-domain (NSDB, Fig. 4B) or G-domain (NSDG, Fig. 4C), and
partially blocked by the non-GTP-binding mutation, G256V
(Fig. 4D). This anti-TRF1 dimerization effect of NS was
unaffected by the A-domain deletion (NSDA, Fig. 4E). Given
that the NSDB and NSDG mutants can both displace TRF1-
bound GNL3L, but cannot block TRF1 homodimerization, we
conclude that the anti-TRF1 dimerization effect of NS is not
determined by its ability to compete against GNL3L for TRF1
binding.
NS decreases TRF1 binding to telomeric DNA in vitro
Because TRF1 binds telomeric DNA as homodimers, we speculate
that NS might regulate the telomeric association of TRF1. To test
whether NS has such a function, we first used the electrophoretic
mobility shift assay (EMSA) to determine the direct effect of NS on
TRF1 binding to double-stranded (TTAGGG)6 probes. Compared
with the probe alone (Fig. 5A1, lane 1) and vector-transfected
sample (Fig. 5A1, lane 2), the Myc-tagged TRF1-transfected
sample (Fig. 5A1, lane 3) yielded a specific TRF1–DNA complex
(black arrow) that could be competed by excess unlabeled probes
(Fig. 5A1, lane 4) and supershifted by anti-Myc antibody (Fig. 5A1,
grey arrow in lane 5). NS by itself did not bind the (TTAGGG)6
Fig. 3. Identification of NS domain required for its ability to inhibit GNL3L binding to TRF1 and vice versa. Affinity binding between GST–TRF1 and
GNL3L (Myc) was conducted in the presence of different NS deletion mutants. The NS ability to block GNL3L binding to TRF1 requires its TRF1-interacting I-
domain (A), but is unaffected by any other deletions (B–D) or the G256V mutation (E). (F) GNL3L mutants used to map the domain(s) required for its
competition with NS for TRF1 binding. The ability of GNL3L to block NS binding to TRF1 requires only its TRF1-interacting G-domain (G) and does not depend
on its BC-domain (H), I-domain (I) or GTP binding (J).
Fig. 4. The anti-TRF1 dimerization
effect of NS requires its basic and
GTP-binding domains, in addition
to its TRF1-binding I-domain.
Agarose-bound GST–TRF1 was
incubated with lysates containing a
fixed amount of TRF1 (Myc) and
increasing amounts of NS deletion
mutants (HA). The NS ability to block
TRF1 dimerization is completely
abolished by deletions of its I-domain
(A), B-domain (B) or G-domain (C),
partially blocked by the GTP-binding
mutant (G256V, D), but is completely
unaffected by the A-domain deletion
of NS (E). Agarose-bound (R) and
supernatant fractions (S) are indicated.


















probe (Fig. 5A1, lanes 7 and 8). A 40% reduction in the TRF1–
DNA complex intensity was noted in the NS overexpression
samples (Fig. 5A1, lanes 9 and 10). Next, we performed chromatin
immunoprecipitation (ChIP) to confirm that NS has an effect on the
telomere binding of TRF1 in vivo. The ChIP results showed that NS
does not bind the telomere by itself or through TRF1 or TRF2
(Fig. 5B, left). In addition, the ChIP experiments showed that NS
does not change the amount of telomere-bound TRF1 (Fig. 5B,
right). These results suggest that NS has little or no effect on
regulating the amount of telomere-bound TRF1 proteins in vivo.
NS reduces the dynamic telomere association of TRF1
Because NS does not affect the static amount of telomere-bound
TRF1, we decided to use the FLIP (fluorescence loss in
photobleaching) approach to investigate whether NS regulates
the dynamic telomere association of TRF1 in live cells. We chose
U2OS cells for the dynamic study because their TRF1–GFP
signals give the best telomere-to-nucleoplasmic ratios compared
with other cell lines we tested. Consistent with the ChIP result,
we found that NS overexpression did not change the static
distribution pattern of TRF1 as detected by immunofluorescence
(Fig. 6A). To study the dynamic telomere association of TRF1, a
FLIP paradigm was designed to measure the telomeric retention
time of TRF1–GFP proteins. In the FLIP experiments, a 1764.6
mm rectangular region in the nucleoplasm was repetitively
bleached and the loss of the TRF1–GFP fluorescent signals at
non-bleached telomeres was recorded over a period of 136
seconds (Fig. 6B). The validity of using the C-terminally GFP-
fused TRF1 to track the distribution of endogenous TRF1
proteins was previously verified (Zhu et al., 2009). The time to
reach half-maximal loss of TRF1 signals (mean decay half-time
[T1/2]) was used as a measurement of its telomeric retention time.
Our FLIP results showed that NS decreases the telomeric
retention of TRF1 (Fig. 6C). The average T1/2 of NS-
overexpressing cells (22.6 seconds) was significantly shorter
than the T1/2 of control cells (33.8 seconds) (P,0.0001, Repeated
Measures ANOVA). Together, our data demonstrate that NS
regulates the dynamic telomere association of TRF1, but not the
static amount of telomere-bound TRF1 proteins.
NS decreases the formation of telomere-dysfunction-
induced foci
Because overexpressed TRF1 reduces the telomere length
presumably by blocking the telomerase from gaining access to
the telomere (van Steensel and de Lange, 1997), we speculated
that NS might help the repair of damaged telomeres by reducing
the telomeric retention of TRF1. To test this possibility, we
measured the number of telomere-dysfunction-induced (TIF) foci
per cell by confocal colocalization of 53BP1 (p53 binding protein
1) and TRF1–GFP signals in TRF2DBDM-transfected U2OS cells
(Fig. 7A). 53BP1 was originally identified as a p53 binding
partner (Iwabuchi et al., 1994) and later shown to be a DNA
damage response protein that is rapidly recruited to sites of DNA
damage (Anderson et al., 2001; Schultz et al., 2000). Notably, we
found that NS had a significant effect in protecting against TIF
formation in TRF2DBDM-transfected cells (Fig. 7B). NS
overexpression (NS-OE) reduced the number of TRF2DBDM-
induced TIF per cell from 4.3 (¡0.2) down to 1.8 (¡0.2)
(P,0.0001, t-test). This effect was TIF-specific, because NS did
not change the number of non-telomere-related DNA damage
foci per cell (non-TIF, defined by the 53BP1+/TRF1–GFP2
Fig. 5. NS reduces the amount of telomere-bound TRF1 in the
electrophoretic mobility shift assay but not in the chromatin
immunoprecipitation experiment. (A1) EMSA experiments identified a
specific TRF1-probe complex (lane 3, indicated by black arrow) that can be
competed by unlabeled probes (lane 4) and supershifted by anti-Myc antibody
(lane 5, indicated by grey arrow). Coexpression of NS reduces the intensity of
the TRF1-DNA complex by 40% (lanes 9 and 10). NS does not bind telomeric
DNAs by itself (lanes 7 and 8) or through TRF1 (lane 10). (A2) Western blots
show input HEK293 nuclear extracts expressing the indicated proteins used
for EMSA experiments. (B) ChIP assays showed that immunoprecipitation of
HA-tagged NS (NS/a-HA) does not co-purify telomeric DNAs (Tel-ChIP)
more than the vector/a-HA (Ctrl/a-HA), NS/IgG, or Alu sequence controls
(left). NS coexpression does not change the amount of telomere-bound TRF1
(TRF1+NS/a-Myc) in ChIP (right).


















signal). The numbers of non-TIF foci per cell are 6.5 (¡0.5) and
6.2 (¡0.4) in the control (Ctrl) and NS-OE groups, respectively
(P50.56). It is also not caused by changing the number of TRF1–
GFP foci per cell (36.9¡1.1 versus 35.5¡1.0 in the control and
NS-OE groups, respectively, P50.38). To check whether this
effect of NS correlates with its ability to decrease the telomeric
retention of TRF1, we measured the FLIP rate of TRF1 in control
and NS-overexpressing cells when telomeres were damaged
(Fig. 7C). The FLIP results showed that the telomere-associated
TRF1 was more dynamic under the TRF2DBDM-transfected
condition (T1/2526.3 seconds, black line) compared with the
control condition (T1/2533.8 seconds, blue line) (P,0.01,
Repeated Measures ANOVA) (Fig. 7D). Upon telomere
damage, NS was capable of further lowering the telomeric
retention time of TRF1 (T1/2518.8 seconds, red line) (P,0.05,
Repeated Measures ANOVA). These results show that NS can
shorten the dynamic association of TRF1 with the telomere and
prevent the formation of TIF in TRF2DBDM-transfected cells.
Discussion
NS and GNL3L regulate TRF1 dimerization in
opposite directions
It is known that TRF1 binds telomeric DNAs as homodimers, but
it is not clear whether non-telomere-bound TRF1 dimerizes first
in the nucleoplasm or does so during its binding to the telomere.
In an attempt to determine the differential activities of NS and
GNL3L on TRF1 regulation, we uncovered an extrachromosomal
mechanism that operates bidirectionally to inhibit or promote
TRF1 dimerization (Fig. 8). Because NS and GNL3L do not bind
telomeric DNAs by themselves or through TRF1 or TRF2, such
activities most likely occur outside the telomere. In a previous
report, we found that GNL3L can promote the dimerization and
telomeric association of TRF1 (Zhu et al., 2009), Here, we
discover that NS binding decreases the GNL3L binding and
homodimerization of TRF1. The ability of NS and GNL3L to
compete against each other for TRF1 binding is probably caused
by a steric hindrance effect, because all NS and GNL3L mutants
with the ability to bind TRF1 are capable of doing so. NS and
GNL3L interact with separate domains of TRF1, that is, the
undefined domain and homodimerization domain (HBD, also
known as TRF homology or TRFH), respectively. Because the
HBD domain of TRF1 also serves as its binding interface for
TIN2 (Chen et al., 2008), this might explain why GNL3L can
compete against TIN2 for TRF1 binding but NS cannot. Mutant
analyses showed that NSDB and NSDG have the ability to block
the GNL3L binding but not the dimerization of TRF1, indicating
that the NS ability to perturb TRF1 dimerization is not
determined by its ability to displace TRF1-bound GNL3L.
NS reduces the telomeric retention time of TRF1
Since TRF1 binds telomeric DNAs as dimers, the NS-mediated
inhibition on TRF1 dimerization may decrease its telomeric
association. Even though this idea is consistent with our EMSA
result, it is not supported by the telomere ChIP data, which show
that the amount of telomere-bound TRF1 in vivo is not affected
by NS perturbation. Instead, the NS effect is mainly on the
dynamic association between TRF1 and the telomere. Based on
these findings, we speculate that NS might have a function in
Fig. 6. NS shortens the telomeric retention time of TRF1. (A) Confocal studies show that the static distribution of TRF1–GFP is not changed by overexpression
of HA-tagged NS (NS-OE) in U2OS cells. Right and bottom panels show enlarged areas indicated by the small rectangles in the left upper panels. Dashed lines
demarcate the nucleo-cytoplasmic boundary. (B) The dynamic telomere association of TRF1 was measured its telomeric retention time using the fluorescence loss
in photobleaching (FLIP) approach in U2OS cells. Time-sequenced images with labels indicating the bleached areas (red rectangles), measured telomeres
(green arrows) and intervals between image acquisition and the first bleaching pulse (in seconds) are shown. (C) NS-OE significantly decreases the telomeric
retention time of TRF1 (P,0.0001, by Repeated Measures ANOVA). Error bars represent s.e.m., shown on one side (indicated by arrows) of the curves. Y-axis
represents the relative fluorescence index (RFI). Top arrows indicate bleaching pulses. Scale bars: 10 mm (A) and 5 mm (B).


















promoting the dynamic exchange between the telomere-bound
and unbound TRF1 proteins by shifting the nucleoplasmic TRF1
from the dimer pool to the monomer pool.
Biological implications of NS-regulated TRF1 dynamics
It has been shown that one of the functions of TRF1 is to block the
telomere access by the telomerase, which negatively affects the
telomere length (van Steensel and de Lange, 1997). At the same
time, TRF1 also has a crucial role in protecting the integrity of the
telomere (Martinez et al., 2009). How these two activities of TRF1
work in sync at the cellular level needs further clarification. We
propose that the telomere-bound TRF1 consists of two dynamically
distinct pools of proteins. The dynamic TRF1 population is
constantly shifting between the telomere-bound state and the non-
telomere-bound state, whereas the stabilized TRF1 population is
held in place by the formation of the telomere-capping complex and
undergoes little exchange with the non-telomere-bound TRF1. We
speculate that the fast-exchanging component of the telomere-
bound TRF1 serves as the precursor of the highly organized
telomere complex on one hand and prevent the telomere access by
the telomere remodelling or repair machinery on the other hand.
The NS function described in this study primarily affects the
retention time of the dynamic (or destabilized) pool of telomere-
bound TRF1, and, therefore, might allow the remodelling and
repair proteins better access to the telomeric DNAs. Given the
preferential expression of NS and GNL3L in the undifferentiated
and differentiated cells, respectively, and their opposite roles in
regulating TRF1 dimerization, one might infer that the telomere-
remodeling capability differs from cell to cell. Undifferentiated
cells, which express high levels of NS and low levels of GNL3L,
might be more active in telomere remodeling and repair than
differentiated cells, which express low levels of NS and high levels
of GNL3L. Because NS and GNL3L are separate genes only in
vertebrates (Tsai and Meng, 2009), such expansion of the
functional repertoire in telomere regulation probably arose during
the evolution of the vertebrate lineage. Of note, the NS effect on
telomere damage prevention was determined in U2OS cells, chosen
for their superior imaging quality of TRF1–GFP and 53BP1 signals
for both static and dynamic studies. U2OS cells belong to the
alternative lengthening of telomeres (ALT) cell type that uses the
homologous recombination (HR) instead of the telomerase-
dependent mechanism for telomere remodeling and repair (Bryan
Fig. 7. NS decreases formation of telomere-dysfunction-induced foci and the telomeric retention time of TRF1 in TRF2DBDM-transfected cells. (A) TIF
formation was induced by TRF2DBDM transfection in U2OS cells. The number of TIF per cell was measured by confocal colocalization of 53BP1 and TRF1–GFP
signals in control (A1) and NS-OE (A2) cells. (B) NS shows a significant effect in reducing the number of TIF per cell (left), but has no effect on the number of
non-telomere-related DNA damage foci (non-TIF, middle), as defined by the 53BP1+/TRF1–GFP2 signal, or the number of total TRF1–GFP foci per cell (right).
(C) Time-sequenced FLIP images of TRF2DBDM-transfected U2OS cells (see Fig. 6B for label description). (D) The FLIP results show that TRF2DBDM expression
decreases the telomeric retention time of TRF1 (black line) compared with the control-transfected cells (blue line) (P,0.01), which supports the idea that
TRF2DBDM destabilizes the telomere-capping complex. Overexpression of NS further accelerates the exchange rate between telomere-bound and unbound TRF1
proteins (red line) (P50.02). Scale bars: 5 mm.


















et al., 1997; Bryan et al., 1995). Therefore, it is possible that if
TRF1 differentially affects the telomere access of telomerase and
HR proteins in telomerase-active and ALT cells, respectively, the
function of NS on telomere damage prevention might also differ in
these two cell types.
In conclusion, this study shows that NS and GNL3L act as
chaperone proteins that regulate the monomeric versus dimeric
forms of non-telomere-bound TRF1. Even though NS and
GNL3L do not take part in the formation of the telomere-
capping complex, they modulate the dynamics of telomere-bound
TRF1, and NS, in particular, has the ability to prevent telomere
damage in TRF2DBDM-transfected cells.
Materials and Methods
cDNA constructs and antibodies
Deletions, point mutations and epitope tagging were introduced using the stitching
PCR strategy as described previously (Meng et al., 2007; Tsai and McKay, 2005).
The N-terminal FLAG-tagged TRF2DBDM construct (containing aa 45–454) was
obtained from Zhou Songyang (Baylor College of Medicine, Houston, TX).
Primary antibodies used here include those against HA (HA.11, Covance), Myc
(9E10, Covance), FLAG (M2, Sigma), TRF1 (TRF-78, Chemicon), 53BP1 (4937,
Cell Signaling), NS (Ab2438, Ab1164 and Ab138) and GNL3L (Ab134).
Cell culture
Procedures for cell culture and plasmid transfection were described in our previous
work (Meng et al., 2007). All biochemical studies were performed in vitro or in
HEK293 cells (Figs 1–5). Dynamic studies were conducted in U2OS cells (Figs 6, 7).
GST pull-down assays and protein purification
For pull-down experiments, GST fusion proteins were expressed using the pGEX
4T-2 vector in BL21/DE3 cells (Tsai and McKay, 2002). Epitope-tagged proteins
were expressed in HEK293 cells and extracted in phosphate-buffered saline (PBS)
with Triton X-100 (1%). Sepharose-bound GST fusion proteins (1–2 mg) were used
for each reaction. To purify NS and GNL3L proteins, GST-fused recombinant
proteins were expressed in BL21/DE3 bacteria, purified by glutathione beads, and
released from the GST backbone by thrombin cleavage.
Coimmunoprecipitation
Protein lysates were extracted in NTEN buffer and incubated with primary
antibody and Protein-G–Sepharose beads (Amersham) for 4 hours at 4 C˚.
Immunoprecipitates were washed with RIPA buffer before SDS-PAGE. For two-
step coimmunoprecipitation, the TRF1 (FLAG-tagged) complex was precipitated
using anti-FLAG antibody and eluted by FLAG peptide incubation. The co-
complex of TRF1 (FLAG-tagged) and GNL3L (HA-tagged) was subsequently
immunoprecipitated from the TRF1 complex using the anti-HA antibody.
Electrophoretic mobility shift assay
EMSA experiments were carried out based on the protocol described previously.
Nuclear extracts were prepared from HEK293 cells transfected with the indicated
constructs. To generate EMSA probes, the (TTAGGG)6 primer was radiolabeled
with [c-32P]ATP in a T4 kinase reaction, annealed with excess amounts of the
(CCCTAA)6 primer, and purified through QIAquick nucleotide removal columns
(Qiagen). Reaction and gel electrophoresis conditions were described previously
(Yasumoto et al., 2007; Zhu et al., 2009).
Chromatin immunoprecipitation
Cells were crosslinked using 1% formaldehyde, lysed in 50 mM Tris buffer with
1% SDS and sonicated to obtain chromatin fragments from 300 bp to 1 kb. The
resulting lysates were incubated with antibodies and Protein-G–Sepharose.
Chromosomal DNA was extracted from the immunoprecipitates by RNase-A
and proteinase-K treatment and reverse crosslinking. DNA samples were dot
blotted and hybridized with a 32P-labeled (TTAGGG)4 or Alu (59-GGC CGG GCG
CGG TGG CTC ACG CCT GTA ATC CCA GCA-39) oligonucleotide probe. All
lysates were normalized based on protein concentrations. A part of the lysate (1/
20th) was used to measure the input DNA amount.
Fluorescence loss in photobleaching
Bleaching experiments were performed in U2OS cells grown on Nalgene Lab Tek
II chamber slides by using a Zeiss LSM510 confocal microscope equipped with a
636 plan-apochromat oil objective, as described previously (Meng et al., 2007).
The FLIP paradigm was modified based on a previously published method
(Mattern et al., 2004). Specifically, we measured the dynamic telomere association
of TRF1 by the rate of fluorescence loss of TRF1–GFP signals on unbleached
telomeres while bleaching a 1764.6 mm rectangular region within the
nucleoplasm with repetitive bleaching pulses of 150 msecond duration and 787
msecond interval. Images were acquired with 36 confocal zoom. The telomeric
relative fluorescence index (RFI) in bleached cells was normalized to the telomeric
intensity of neighboring non-bleached cells after background subtraction using the
calculation: RFI5(It/I0)*(C0/Ct), where It and I0 are the background-subtracted
intensities of the telomere in the bleached cell at time-point t and before
photobleaching, respectively (Phair and Misteli, 2000). Ct and C0 are the
background-subtracted intensities of the telomere in the neighboring non-bleached
cell at time-point t and before photobleaching, respectively. The telomeric RFI
were measured from 24 cells collected from two independent experiments. For
every cell, the RFI represents the average of six telomeres in random positions.
Confocal quantification of telomere dysfunction-induced foci
TIF were determined by the colocalization of 53BP1 and TRF1–GFP signals. Images
were acquired using a Zeiss LSM510 confocal microscope using a 636 plan-
apochromat oil objective (1.4 NA). Scanning was set with a 5126512 frame size,
36 zoom, and,1.0 mm optical thickness. Stacked images of 60 cells were collected
at 0.5 mm intervals from three independent experimental repeats, and using ImageJ
1.36b software.
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Fig. 8. Opposing regulation of TRF1 dimerization and telomere
association by NS and GNL3L. We propose that the dimerization of TRF1 is
oppositely regulated by NS and GNL3L before it binds to the telomere. In this
pre-telomeric phase, GNL3L promotes and NS inhibits the dimerization of
non-telomere-bound TRF1. The relative amount of TRF1 monomers versus
dimers in the nucleoplasm determines the telomeric retention time of a
dynamic pool of telomere-bound TRF1, which might serve the function of
blocking the telomeric access of telomere remodelling and repair proteins and
as the precursor for the stably bound TRF1 that protects the integrity of
the telomere.
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